Tatar Gamze, Ergül Nurhan, Baloğlu Mehmet Can, Arslan Esra, Çermik Tevfik Fikret
From the University of Health Sciences, Department of Nuclear Medicine, Istanbul Bagcilar Training and Research Hospital.
University of Health Sciences, Clinic of Nuclear Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.
Clin Nucl Med. 2023 Mar 1;48(3):e135-e137. doi: 10.1097/RLU.0000000000004522. Epub 2023 Jan 10.
A 79-year-old man with prostate cancer was evaluated with 68Ga-prostate-specific membrane antigen (PSMA), 68Ga-FAPI-04, and 18F-FDG PET/CT scans since a rise in prostate-specific antigen was seen at last control while receiving chemotherapy. Abnormal FDG uptakes were observed in the tumoral areas of the left half of the prostate and walls of the bladder, although PSMA and FAPI activity were absent or lower in the relevant tumoral areas. Restaging 68Ga-PSMA and 18F-FDG PET/CT scans were obtained on the patient whose progression continued after transurethral tumor resection. Herein, we present a case proving intraindividual tumor heterogeneity in prostate cancer underwent PET/CT imaging with 3 different radiopharmaceuticals.
一名患有前列腺癌的79岁男性，在接受化疗期间上次检查时前列腺特异性抗原升高，因此接受了68Ga-前列腺特异性膜抗原（PSMA）、68Ga-FAPI-04和18F-FDG PET/CT扫描评估。在前列腺左半部分的肿瘤区域和膀胱壁观察到异常的FDG摄取，尽管在相关肿瘤区域PSMA和FAPI活性缺失或较低。对经尿道肿瘤切除术后病情仍持续进展的患者进行了68Ga-PSMA和18F-FDG PET/CT扫描重新分期。在此，我们报告一例病例，该病例证明了前列腺癌患者在接受3种不同放射性药物的PET/CT成像时存在个体肿瘤异质性。
